US OptionsDetailed Quotes

OPRX241220P10000

Watchlist

0.00
0.000.00%

15min DelayClose Nov 27 09:30 ET

0.00High0.00Low

OptimizeRx Stock Discussion

Jaguar8

Sep 10 07:09

NEWS

$OptimizeRx (OPRX.US)$
OptimizeRx Continues to Expand its Strategic Relationship with a Top-Tier Pharma Client via a Multi-Brand, Multi-Solution Investment Commitment with Over $10M In-Year Total Value
OptimizeRx Corp. (Nasdaq: OPRX) has expanded its strategic relationship with a major pharma client, resulting in a multi-solution, multi-brand program with a total in-year commitment of over $10 million. This includes the previously mentioned $6 million DAAP contract, which is still undergoing ...

Moomoo AI

Mar 15 07:14

Recent insider selling at OptimizeRx, especially by Marion Odence-Ford, may worry potential investors. The absence of insider buying and insignificant share ownership by insiders hint at possible doubts about future performance.

OptimizeRx's Stock Sinks To US$12.92, But Insiders Sold Even Lower

Moomoo AI

Dec 21, 2023 06:04

OptimizeRx's high P/S ratio may suggest that investors anticipate a turnaround in the company's revenue performance. This could indicate shareholders' strong future revenue expectations.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 06:01

The high P/S ratio at OptimizeRx suggests investors expect a reversal of the company's downtrend in revenue. Shareholders seem to hold stocks with hope for the company's promising future.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 06:01

Investors at OptimizeRx might be anticipating a reversal in its poor revenue performance, hence the high P/S ratio. Shareholders potentially retain stocks expecting the company's bright future.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Dec 21, 2023 05:54

Investors at OptimizeRx may be expecting a turnaround in the company's poor revenue performance, hence the high P/S ratio. This could reflect shareholders' strong future revenue expectations.

Investors Appear Satisfied With OptimizeRx Corporation's (NASDAQ:OPRX) Prospects As Shares Rocket 40%

Moomoo AI

Nov 14, 2023 04:43

Analysts exhibit growing optimism towards OptimizeRx, driven by notable hike in revenue expectations. The current market conditions indicate a potential good time for reassessing OptimizeRx.

News Flash: Analysts Just Made A Huge Upgrade To Their OptimizeRx Corporation (NASDAQ:OPRX) Forecasts

Moomoo Breakfast US

Aug 10, 2022 07:45

Columns Today's pre-market stock movers: RBLX, TTD, VLD, WYNN and more

Gainers:
In reaction to earnings/guidance:
• $The Trade Desk (TTD.US)$+17%, $Workiva (WK.US)$ +15.3%, $Arlo Technologies (ARLO.US)$ +12%, $Array Technologies (ARRY.US)$ +10.3%, $Everbridge (EVBG.US)$ +9.7%, $Catalyst Pharmaceuticals (CPRX.US)$ +9.4%, $Halozyme Therapeutics (HALO.US)$ +8.7%, $Velo3D (VLD.US)$ +7.6%, $CyberArk (CYBR.US)$ + 6.2%, $Haemonetics (HAE.US)$ +5.8%, $Jackson Financial (JXN.US)$ +5.7% (also increases dividend), $Axon Enterprise (AXON.US)$ +4.8%,...

Analysts Notebook

Jul 15, 2022 07:38

Columns Top upgrades and downgrades on 7/15: QCOM, DAL, CSCO, DRE and more

Upgrades
• $Allogene Therapeutics (ALLO.US)$ : Goldman Sachs Upgrades to Buy from Neutral - PT $32 (from $9)
• $ChampionX (CHX.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $22 (from $25)
• $CSX Corp (CSX.US)$ : Stifel Upgrades to Buy from Hold - PT $37 (from $39)
• $TechnipFMC (FTI.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $8 (from $9.50)
• $Norfolk Southern (NSC.US)$ : Stifel Upgrades to Buy from Hold - PT $2...

Analysts Notebook

Jul 1, 2022 06:54

Columns Top upgrades and downgrades on 7/1: CMCSA, FDX, XPEV, HOG and more

Upgrades
• $Coupang (CPNG.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $19 (from $28)
• $First Republic Bank (FRC.US)$ : Atlantic Equities Upgrades to Overweight from Neutral - PT $188 (from $210)
• $Sitio Royalties (STR.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $43 (from $36)
Downgrades
• $Duck Creek Technologies (DCT.US)$ : JMP Securities Downgrades to Market Perform from Market Outperform
•...

No comment yet